Tesla plans to invest more than $700 million to expand its Texas plant

/ / Consumer Discretionary /

Tesla’s electric car factory in Austin, Texas, will reportedly begin to expand in the coming weeks. On January 9, local time, Tesla said in a document submitted to the Texas Department of Licensing and Regulation (TDLR) that it plans to invest $717 million to build four new buildings at the Austin factory as early as the end of this month, with a total construction area of 1.4 million square feet.

Tesla plans to invest more than $700 million to expand its Texas plant Read Post »

JPMORGAN CHASE & CO. (NYSE:JPM) net revenue of $35.57 B ,YoY+18%

/ / Financials /

JPMORGAN CHASE & CO. (NYSE:JPM) Stock price trend forecast and trading range: Updated to: 2023.1.13 (Note: The upper red line in the picture is the resistance, and the lower red line is the support) Analysis from stock chart —————————————————————- Short-term trend: bullish Sell high and buy low of range : $135 – $142 Support: $135 resistance: $142 Stop Loss Price: $135 price target: $142 Buy the position again: stop falling Medium-term trend: bullish High sell low buy range: $132 – $142 Support: $132 resistance: $142 Stop Loss price: $132 price target: $142 Buy the position again: stop falling Long-term trend: bullish High sell low buy of range: $130 – $142 Support : $130 resistance: $142 Stop Loss price: $130 price target : $142 Buy the position again: stop falling From Analysis from financial statements: January 13, 2023 In fiscal 2022, Q4 achieved revenue of $35.57 billion, YoY+18%, market expectations of

JPMORGAN CHASE & CO. (NYSE:JPM) net revenue of $35.57 B ,YoY+18% Read Post »

Jefferies Financial (NYSE:JEF) revenue of $1.43 billion in 2022 Q4 , YoY-18%

/ / Financials /

Jefferies Financial Group Inc.(NYSE:JEF) Stock price trend forecast and trading range: Updated to: 2023.1.12 (Note: The upper red line in the picture is the resistance, and the lower red line is the support) Analysis from stock chart —————————————————————- Short-term trend: bullish Sell high and buy low of range : $38 – $43 Support: $38 resistance: $43 Stop Loss Price: $38 price target: $43 Buy the position again: stop fall Medium-term trend: bullish High sell low buy range: $38 – $43 Support: $38 resistance: $43 Stop Loss price: $38 price target: $43 Buy the position again: stop fall Long-term trend: bullish High sell low buy of range: $36 – $43 Support : $38 resistance: $43 Stop Loss price: $38 price target : $43 Buy the position again: stop fall From Analysis from financial statements: Fourth Quarter 2022 revenue of $1.43 billion, YoY-18%, net income  of $0.14 billion, YoY-57%, EPS $0.57. Historical

Jefferies Financial (NYSE:JEF) revenue of $1.43 billion in 2022 Q4 , YoY-18% Read Post »

Meta Platforms  (NASDAQ:META) stock price trend forecast and trading range -2023.1.12

/ / Technology /

Meta Platforms  (NASDAQ:META) Stock price trend forecast and trading range: Updated to: 2023.1.12 (Note: The upper red line in the picture is the resistance, and the lower red line is the support) Analysis from stock chart —————————————————————- Short-term trend: bullish Sell high and buy low of range : $130 – $140 Support: 20-day moving average resistance: $140 Stop Loss Price: $130 price target: $140 Buy the position again: stop fall Medium-term trend: bullish High sell low buy range: $128 – $150 Support: 20-day moving average resistance: $150 Stop Loss price: $128 price target: $150 Buy the position again: stop fall Long-term trend: stop falling and rebound High sell low buy of range: $125 – $155 Support : 30-day moving average resistance: $155 Stop Loss price: $125 price target : $155 Buy the position again: stop fall From Analysis from financial statements: From the analysis of financial statements, Q3 of fiscal

Meta Platforms  (NASDAQ:META) stock price trend forecast and trading range -2023.1.12 Read Post »

Tesla, Inc. (Nasdaq:TSLA) Stock price trend forecast and trading range -2023.1.12

/ / Consumer Discretionary /

Tesla, Inc.(Nasdaq:TSLA) Stock price trend forecast and trading range: Short-term stock prices may temporarily stop falling, and the mid-term needs to be reconfirmed, but the market performance is weaker than the index, and the downside risk when the index pulls back is emphasized. Updated to: 2023.1.12 (Note: The upper red line in the picture is the resistance, and the lower red line is the support) Analysis from stock chart —————————————————————- Short-term trend: bullish Sell high and buy low of range : $110 – $125 Support: $100 resistance: $125 Stop Loss Price: $110 price target: $125 Buy the position again: stop fall and rise to $100 Medium-term trend: neutral High sell low buy range: $110 – $155 Support: $100 resistance: $155 Stop Loss price: $110 price target: $155 Buy the position again: stop fall and rise to $100 Long-term trend: bearish High sell low buy of range: none Support : $100

Tesla, Inc. (Nasdaq:TSLA) Stock price trend forecast and trading range -2023.1.12 Read Post »

Moderna (NASDAQ:MRNA):announced updates on its industry-leading mRNA pipeline

/ / Health Care /

January 9, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities. Respiratory syncytial virus (RSV) vaccine •Pivotal Phase 3 RSV efficacy study (mRNA-1345) in older adults (60+) has enrolled 36,604 participants •Primary endpoints are safety and vaccine efficacy •The Phase 3 RSV study has now accrued the cases required (64 confirmed cases with 2+ symptoms accrued, minimum of 42 required) to complete our first interim efficacy analysis Seasonal influenza vaccine •mRNA-1010 Southern Hemisphere immunogenicity study in adults (18+) is fully enrolled (6,000 participants); data readout expected in 1Q23 •mRNA-1010 Northern Hemisphere efficacy study in older adults (50+) is fully enrolled (22,510 participants); data readout could occur this winter depending upon cases

Moderna (NASDAQ:MRNA):announced updates on its industry-leading mRNA pipeline Read Post »

Moderna (NASDAQ:MRNA):2022 COVID-19 vaccine sales of approximately $18.4 billion

/ / Health Care /

January 9, 2023 / Moderna, Inc. (NASDAQ:MRNA),announced updates on its industry-leading mRNA pipeline. 2022 COVID-19 vaccine sales of approximately $18.4 billion (unaudited). Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals. Potential additional contracts in the United States, Europe, Japan, and other key markets. About Moderna (NASDAQ:MRNA) In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and

Moderna (NASDAQ:MRNA):2022 COVID-19 vaccine sales of approximately $18.4 billion Read Post »

Scroll to Top